Voronoi Co. Ltd. (310210.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea

Price
106,300.00 KRW
Market cap
1.91 tn KRW
P/E (2025)
–
P/S (2025)
254.56
Dividend yield
0.00 %
Net margin
-568.49 %
Return on equity (ROE)
-41.14 %
Return on assets (ROA)
-24.94 %

Voronoi Co. Ltd. financials

Fiscal year20242025
Revenue0.00 KRW7.51 bn KRW
Gross profit–7.51 bn KRW
Operating income-36.34 bn KRW-54.38 bn KRW
EBIT-32.06 bn KRW-47.99 bn KRW
Net income-32.61 bn KRW-42.71 bn KRW
Diluted EPS – continuing operations-1,815.23 KRW-2,373.93 KRW

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Voronoi Co. Ltd.

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.